

THE REMARKS

The Amendments

Claims 1, 4, and 5 are amended in response to Restriction Requirement. The amendment in Claim 1 is supported by Claim 3 as filed.


New Claims 18 and 19 are supported by Claim 4 as filed.

No new matter is introduced in any of the amendments. The Examiner is requested to enter the amendments.

The Response

In response to the restriction requirement, Applicants are electing Group 9, Claims 1-17 (in part), drawn to a method of treating pain comprising administering to a subject an effective amount of a compound of Formula I, wherein said compound is not embraced by Formula V, VI, VII, VIII, IX, X, or XI as depicted in Claim 7, for prosecution.


In response to the species election requirement, Applicants are electing 2-{2-Biphenyl-4-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethoxy}-nicotinic acid. The structure is shown below (see Application at page 23, bottom left).



Claims 1, 4-6, and 8-19 read upon the elected species.

Respectfully submitted,

Date: July 9, 2008



Viola T. Kung, Ph.D. (Reg. No. 41,131)

HOWREY, LLP
2941 Fairview Park Drive,
Box 7
Falls Church, VA 22042
Tel: (650) 798-3570
Fax: (650) 798-3600